Sihuan Pharmaceutical Announces Publication of Final BRIGHT-2 Phase 3 Results for Bireociclib in JAMA Oncology

Key Highlights for Investors

• Final Phase 3 Data Published in Top-Tier Journal: The results of the BRIGHT-2 Phase 3 clinical trial evaluating Bireociclib, a novel CDK2/4/6 inhibitor developed by Xuanzhu Biopharm (a non-wholly-owned subsidiary of Sihuan Pharmaceutical), have been published in JAMA Oncology (Impact Factor 20.1).
• Significant Efficacy Demonstrated: Bireociclib, in combination with Fulvestrant, showed a statistically and clinically significant improvement in median progression-free survival (mPFS) for patients with HR+/HER2- advanced breast cancer who had progressed after prior endocrine therapy.
• Robust and Durable Antitumor Activity: The final analysis, with a median 19-month follow-up, confirmed durable survival benefits, with mPFS extended to 14.7 months (Bireociclib group) vs. 7.3 months (placebo group), reducing the risk of progression or death by 46% (HR=0.54, P<0.001). Independent review showed mPFS of 17.5 months with Bireociclib vs. 7.3 months, a 53% risk reduction (HR=0.47, P<0.001).
• Strong Objective Response Rates: The combination therapy achieved a 50.3% objective response rate (ORR), compared to 16.7% in the placebo group, and the median duration of response had not been reached at data cutoff, indicating sustained efficacy.
• Broad Efficacy Across Patient Subgroups: Consistent benefits were seen in high-risk groups, including those with primary endocrine resistance, premenopausal/perimenopausal status, short disease-free interval (DFI ≤24 months), and those with ESR1, PIK3CA, or TP53 mutations. In premenopausal/perimenopausal patients, risk of progression or death was reduced by 62% (HR=0.38).
• Favorable Safety Profile: Bireociclib’s design as a highly selective CDK4 inhibitor (with weaker CDK6 inhibition) mitigates hematopoietic suppression, allowing a continuous BID regimen and steady drug exposure. Common side effects like diarrhea and neutropenia were manageable and did not accumulate over time.
• Regulatory and Reimbursement Milestones: Bireociclib (brand name: Xuan Yue Ning) is the first CDK2/4/6 inhibitor approved in China for both combination and monotherapy in HR+/HER2- advanced breast cancer. It gained regulatory approval in May 2025 (with additional approvals in March 2026), and its indications were included in the National Reimbursement Drug List from January 1, 2026, expanding patient access and potential market uptake.

Details for Shareholders and Potential Price-Sensitive Developments

• Strong Clinical Data: The publication in a high-impact journal and robust final analysis data further validate Bireociclib’s efficacy and safety profile. These developments support wider physician adoption and competitive positioning in the Chinese breast cancer treatment market.
• Market Differentiation: Bireociclib is currently the only CDK2/4/6 inhibitor in China with a monotherapy indication, a significant market differentiator that could drive prescription growth, especially among patients resistant to other lines of endocrine therapy.
• Reimbursement Inclusion: The inclusion in the National Reimbursement Drug List for 2025 significantly reduces out-of-pocket costs for patients and is likely to drive sales volume, enhancing revenue visibility for Sihuan Pharmaceutical and Xuanzhu Biopharm.
• Strategic Importance: The successful late-stage development and regulatory approval of Bireociclib reinforce Sihuan’s R&D capabilities and pipeline value, potentially impacting investor perception and share valuation positively.

Comprehensive Summary

Sihuan Pharmaceutical Holdings Group Ltd. (Stock Code: 0460) announced that the final Phase 3 analysis of Bireociclib (Xuan Yue Ning), an innovative CDK2/4/6 inhibitor developed by its subsidiary Xuanzhu Biopharm (02575.HK), was recently published in JAMA Oncology, a world-leading oncology journal.

The BRIGHT-2 study, a multicenter, randomized, double-blind, placebo-controlled trial conducted across 64 hospitals in China, assessed the efficacy and safety of Bireociclib plus Fulvestrant in women with HR+/HER2- advanced breast cancer that had progressed following prior endocrine therapy. The final analysis involved a follow-up of 19 months, extending the interim findings previously published in Nature Communications.

Key findings include a marked extension in progression-free survival (mPFS), with Bireociclib plus Fulvestrant achieving 14.7 months vs. 7.3 months for placebo (HR=0.54, P<0.001), and even greater benefit (17.5 vs. 7.3 months, HR=0.47, P<0.001) by independent review. The ORR was robust at 50.3% (vs. 16.7% for placebo), and the duration of response remains ongoing, supporting long-term disease control. Notably, efficacy was maintained across all major high-risk subgroups, including those with molecular markers of endocrine resistance.

Bireociclib’s unique pharmacological profile—potent inhibition of CDK4/6 while minimizing hematologic toxicity—supports a convenient BID dosing regimen and improved tolerability compared to traditional CDK4/6 inhibitors. The safety profile remained manageable, with early-onset adverse events effectively controlled through clinical management and dose adjustments, and no evidence of cumulative toxicity.

Regulatory milestones further enhance Bireociclib’s commercial outlook. It is the first and only CDK2/4/6 inhibitor in China approved for both combination and monotherapy use in HR+/HER2- breast cancer. With reimbursement secured for its initial indications in the 2025 National Reimbursement Drug List (effective January 2026), the drug is well positioned for rapid patient uptake and revenue growth.

For shareholders, these developments are highly significant: the robust clinical data, prestigious publication, and positive reimbursement decisions collectively strengthen Sihuan Pharmaceutical’s competitive position in the oncology market and could serve as key drivers of share price appreciation.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisers before making any investment decisions. The information provided is based on the company’s official announcement and may be subject to further updates or changes.

View SIHUAN PHARM Historical chart here